Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.
Industries
Nr. of Employees
medium (51-250)
Progenics Pharmaceuticals
Patents
Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
US-12224067-B1
View DetailsSystems and methods for secure cloud-based medical image upload and processing
US-12032722-B2
View DetailsSystems and methods for automated and interactive analysis of bone scan images for detection of metastases
US-11937962-B2
View DetailsNetwork for medical image analysis, decision support system, and related graphical user interface (GUI) applications
US-11894141-B2
View DetailsSystems and methods for artificial intelligence-based image analysis for cancer assessment
US-11564621-B2
View DetailsSystems and methods for secure cloud-based medical image upload and processing
US-11544407-B1
View Details
Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
US-12224067-B1
View DetailsSystems and methods for secure cloud-based medical image upload and processing
US-12032722-B2
View DetailsSystems and methods for automated and interactive analysis of bone scan images for detection of metastases
US-11937962-B2
View DetailsNetwork for medical image analysis, decision support system, and related graphical user interface (GUI) applications
US-11894141-B2
View DetailsSystems and methods for artificial intelligence-based image analysis for cancer assessment
US-11564621-B2
View DetailsSystems and methods for secure cloud-based medical image upload and processing
US-11544407-B1
View DetailsProducts
PNT2002
A small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 3 clinical trials.
LNTH-1095
A small molecule PSMA-targeted 131I-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 2 clinical trials.
LNTH-1404
A Tc-99m-labeled molecule used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer and metastases, currently in Phase 3 clinical trials.
PSMA-TAC
A PSMA-targeted antibody in initial development for metastatic castration-resistant prostate cancer, currently in Phase 1 clinical trials.
LNTH-1558
A small molecule PSMA-targeted agent in pre-clinical development for prostate cancer.
PNT2003
A somatostatin receptor-targeted radioligand therapy with 177Lu for gastroenteropancreatic neuroendocrine tumors, currently in regulatory filing stage.
PNT2002
A small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 3 clinical trials.
LNTH-1095
A small molecule PSMA-targeted 131I-based radioligand therapy for metastatic castration-resistant prostate cancer, currently in Phase 2 clinical trials.
LNTH-1404
A Tc-99m-labeled molecule used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer and metastases, currently in Phase 3 clinical trials.
PSMA-TAC
A PSMA-targeted antibody in initial development for metastatic castration-resistant prostate cancer, currently in Phase 1 clinical trials.
LNTH-1558
A small molecule PSMA-targeted agent in pre-clinical development for prostate cancer.
PNT2003
A somatostatin receptor-targeted radioligand therapy with 177Lu for gastroenteropancreatic neuroendocrine tumors, currently in regulatory filing stage.